Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEFIGAN
NCT01738035Phase 2Completed
- Sponsor
- Calliditas Therapeutics AB
- Start
- Dec 2012
- Primary completion
- Jun 2015
- Modality
- Drug Delivery Systems, Orthosteric Ligands
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial of nefecon in IgA nephropathy (IgAN) (3 arms), sponsored by Calliditas Therapeutics AB. Primary endpoint: Urine Protein Creatinine Ratio at 9 months. Started Dec 2012; status: completed.
02
Drugs
nefecon
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT01738035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01738035.